

RANDOX

SARS-CoV-2 IgG (RBD & NP) ARRAY CE

Uniquely measuring antibodies reactive to both RBD and NP

- Simultaneous detection of IgG antibodies to RBD & NP maximises assay sensitivity reducing false negatives
- Compatible with capillary and venous blood collection
- Distinguish vaccinated from naturally infected individuals
- Identify incidence of SARS-CoV-2 infection in vaccinated individuals
- Confirmation of an adaptative immune response to SARS-CoV-2
- Specificity of 99.5% and sensitivity of 100% ≥ 10 days post SARS-CoV-2 PCR confirmation
- Qualitative and semi-quantitative results provided

Available on Evidence Investigator & Evidence+, the Randox CE marked SARS-CoV-2 IgG (RBD & NP) Array utilises patented Biochip Array Technology (BAT) to simultaneously detect IgG antibodies reactive to both leading COVID-19 diagnostic antigens Spike Receptor Binding Domain (RBD) and Nucleocapsid Protein (NP).

marketing@randox.com
www.randox.com

LT797SEP21

RANDOX

Nucleocapsid Protein (NP)

- Considered the most immunogenic SARS-CoV-2 protein
- Antibody response to NP develops earlier than RBD

Spike Receptor Binding Domain (RBD)

- Primary target for SARS-CoV-2 vaccines and neutralising antibodies
- Antibody response to RBD more persistent than NP over time



AVAILABLE PLATFORMS

Evidence Investigator

- Cost effective and efficient semi-automated multiplex testing solution
- Medium to high throughput (54 samples in 1.5 hours)
- Limited sample volume requirement (10µl)
- Comprehensive immunoassay and molecular test menu available

Evidence+

- Fully automated batch immunoanalyser for faster testing & accurate results
- High throughput (2070 samples per day)
- Limited sample volume requirement (10ul)
- Comprehensive immunoassay test menu available

ORDERING INFORMATION

SARS-CoV-2 IgG (RBD & NP) Array	**EV4447**
SARS-CoV-2 IgG (RBD & NP) Array Control	**EV4448**
Evidence Investigator Analyser	**EV3602**
Evidence+ Analyser	**EV4400**